Cytosorbents Corporation

NasdaqCM:CTSO Stock Report

Market Cap: US$51.2m

Cytosorbents Future Growth

Future criteria checks 2/6

Cytosorbents is forecast to grow earnings and revenue by 53.6% and 27.8% per annum respectively while EPS is expected to grow by 53.9% per annum.

Key information

53.6%

Earnings growth rate

53.9%

EPS growth rate

Medical Equipment earnings growth16.5%
Revenue growth rate27.8%
Future return on equityn/a
Analyst coverage

Low

Last updated03 Jan 2025

Recent future growth updates

Recent updates

The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Oct 01
The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Jul 04
Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13
Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

May 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 08
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents secures $4.3M contract by U.S. Department of Defense

Oct 06

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

Earnings and Revenue Growth Forecasts

NasdaqCM:CTSO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202765-3-2-12
12/31/202653-9-12-113
12/31/202543-13-21-203
12/31/202439-16-26-263
9/30/202438-19-19-18N/A
6/30/202437-26-22-21N/A
3/31/202437-28-24-23N/A
12/31/202336-29-23-22N/A
9/30/202337-23-22-21N/A
6/30/202336-26-24-22N/A
3/31/202335-31-30-23N/A
12/31/202235-33-35-28N/A
9/30/202236-41-36-28N/A
6/30/202238-36-34-26N/A
3/31/202241-29-24-20N/A
12/31/202143-25-18-14N/A
9/30/202144-16-12-10N/A
6/30/202145-10-11-9N/A
3/31/202143-9-7-5N/A
12/31/202041-8-7-6N/A
9/30/202036-11-10-9N/A
6/30/202032-17-12-11N/A
3/31/202028-18-17-16N/A
12/31/201925-19-18-17N/A
9/30/201924-21-17-15N/A
6/30/201923-17-14-13N/A
3/31/201923-19-14-13N/A
12/31/201823-17-12-11N/A
9/30/201821-15-10-9N/A
6/30/201819-14N/A-8N/A
3/31/201817-10N/A-7N/A
12/31/201715-9N/A-6N/A
9/30/201714-11N/A-7N/A
6/30/201712-10N/A-7N/A
3/31/201711-11N/A-7N/A
12/31/201610-12N/A-7N/A
9/30/20168-9N/A-8N/A
6/30/20167-10N/A-8N/A
3/31/20166-5N/A-8N/A
12/31/20155-9N/A-9N/A
9/30/20154-17N/A-9N/A
6/30/20154-17N/A-9N/A
3/31/20154-21N/A-8N/A
12/31/20144-19N/A-6N/A
9/30/20144-9N/A-5N/A
6/30/20144-8N/A-4N/A
3/31/20143-7N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTSO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CTSO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CTSO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CTSO's revenue (27.8% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: CTSO's revenue (27.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 18:20
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cytosorbents Corporation is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffBrean Capital
Jason KolbertD. Boral Capital LLC.
Swayampakula RamakanthH.C. Wainwright & Co.